Russia's Gem-Standard to build one of country's largest plants for blood plasma drugs

Gem-Standard, one of Russia’s largest producers of drugs on the basis of blood plasma, has invested more than $100 million in the building of a new plant, which is located in the Novoorlovskaya special economic zone in St Petersburg, reports The Pharma Letter’s local correspondent.

According to the company, the annual revenue of the enterprise will be 2.5 billion roubles ($43.5 million), while planned production volume is 500,000 packages per year.

The range of the facility will include blood substitutes, blood clotting factors, intravenous immunoglobulins, human-protein-based substance and some other drugs.